STUDY TO ASSESS THE EFFICACY AND SAFETY OF ATULIFLAPON IN MODERATE-TO-SEVERE UNCONTROLLED ASTHMA

Overview: This clinical trial by AstraZeneca evaluates Atuliflapon for treating moderate-to-severe uncontrolled asthma. It's a 12-week, randomized, double-blind, placebo-controlled Phase 2 study involving 666 participants aged 18-80.

Interventions: Participants receive daily oral doses of Atuliflapon or placebo.

Primary Outcome: Time to first CompEx Asthma event.

Secondary Outcomes: Lung function, asthma control, symptom scores, and safety.

Inclusion Criteria:

  • Adults aged 18-80 with moderate-to-severe asthma.

  • Documented asthma diagnosis for at least 12 months.

  • Uncontrolled asthma despite high-dose ICS and LABA.

Exclusion Criteria:

  • Current smokers or recent ex-smokers.

  • Other significant respiratory disorders.

  • Recent participation in other clinical trials.

Dates:

  • Start: January 27, 2022

  • Completion: January 29, 2025

For detailed information, visit the ClinicalTrials.gov page.